Arcturus Therapeutics: Advancing mRNA Technology for Infectious Diseases and Rare Disorders

Arcturus Therapeutics Advances mRNA Technology in Infectious Disease and Rare Disorders

Arcturus Therapeutics Holdings Inc., a pioneer in the field of messenger RNA (mRNA) medicines, is at the forefront of developing innovative therapeutic solutions for infectious diseases and rare genetic disorders. Founded in 2013 and based in San Diego, Arcturus leverages its proprietary technologies, including the LUNAR® lipid-mediated delivery system and STARR® mRNA Technology, to create a robust pipeline of RNA-based therapeutics. These cutting-edge technologies enable the efficient delivery and amplification of mRNA, opening new avenues for treatment and vaccination against a variety of diseases.

Among its notable achievements, Arcturus successfully developed KOSTAIVE®, recognized as the world’s first self-amplifying mRNA COVID vaccine, which has already received regulatory approval. This landmark achievement not only showcases the potential of self-amplifying mRNA platforms but also positions Arcturus as a key player in the rapidly evolving mRNA vaccine landscape. The company’s strategic collaborations, such as the global partnership with CSL Seqirus, enhance its capacity to produce mRNA vaccines, while its joint venture in Japan, ARCALIS, focuses on the manufacturing of mRNA therapeutics. These collaborations underscore Arcturus's commitment to addressing both global health challenges and localized healthcare needs through innovative vaccine solutions.

In addition to its work on infectious diseases, Arcturus is actively pursuing therapies for rare conditions like ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). The company’s expansive intellectual property portfolio, boasting over 400 patents and applications worldwide, solidifies its competitive edge in the nucleic acid medicine arena. This strong patent position not only protects its proprietary technologies but also enables Arcturus to explore diverse applications in gene editing and RNA therapeutics. With its ongoing research and development efforts, Arcturus Therapeutics remains poised to make significant contributions to the treatment of both infectious diseases and rare genetic disorders.

In other developments, Joseph Payne, the President and CEO of Arcturus, is scheduled to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. His presentation will likely provide further insights into the company’s strategic direction and its advancements in mRNA technology. For those interested in learning more about Arcturus Therapeutics and its innovative programs, the company maintains an informative presence on its Investor Relations website and various social media platforms.